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Mel, LFA-I, and p150,95 are structurally related glycoproteins of the CD1 l/CD18 
complex that are expressed on the membrane of human leukocytes. In the neutrophil, 
the surface expression of the CD1 l/CD18 complex is up-modulated (Mel > p150,95 % 
LFA-1) by stimulatory factors that include calcium ionophore A23187, phorbol myristate 
acetate (PMA), and N-L-formyl-L-leucyl-L-phenylalanine (fMLP). Here, in an immuno- 
fluorescence analysis, we have examined CD1 l/CD18 glycoprotein expression by 
human monocytes, pulmonary alveolar macrophages (PAM, obtained by bronchoal- 
veolar lavage), and breast milk macrophages (BMM) as compared to neutrophils before 
and after exposure to A23187 (1 pw, fh4LP (0.1 pm, or PMA (0. I kg/ml) for 15 min at 
37°C. Unstimulated monocytes within unfractionated blood mononuclear cells kept at 
4°C (n = 13) expressed all three CDllKDl8 glycoproteins, and exposure to A23187 
resulted in significant increases in the surface expression of Mol (median of 5.7-fold), 
LFA-1 (median of 2.1-fold), and pl50,95 (median of 7.2-fold). Exposure to WLP- or 
PMA-stimulated increases of lesser magnitude. CD1 l/CD18 expression by PAM (n = 9) 
was barely detectable and was unaffected by exposure to A23187. In contrast, BMM (n 
= 11) expressed all three CD1 l/CD18 glycoproteins (with considerable variability 
among specimens), but no increase was stimulated by A23187. These results demon- 
strate that monocytes, like neutrophils, have the capacity to respond to activating 
factors with an increase in CD1 l/CD18 glycoprotein expression; macrophage differen- 
tiation is accompanied by a loss (PAM) or retention (BMM) of CD1 l/CD18 expression 
that is unmodulated in response to activation. o 198x Academic PRSS. Inc. 
INTRODUCTION 
The CDll/CD18 complex consists of three plasma membrane glycoproteins, 
Mol (CD1 lb/CD18), LFA-1 (CD1 la/CD18), and p150,95 (CD1 lc/CD18), ex- 
pressed by murine and human leukocytes (see (1, 2) for reviews). These mole- 
cules are heterodimeric glycoproteins, each consisting of a distinct higher molec- 
ular weight (Y subunit (containing the CDlla, b, and c antigenic epitopes) that is 
noncovalently associated with a structurally identical 9%kDa l3 subunit (con- 
taining the CD18 epitope). The generation of several murine monoclonal anti- 
bodies specific for the CDlla, b, c, and CD18 epitopes has made it possible to 
quantitate the expression of these glycoproteins on the cell surface and to ascer- 
tain their functional significance in vitro. Mol (CDllbKD18; gp 155,95) is ex- 
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pressed by human neutrophils, monocytes and certain macrophages, null cells, 
and myeloid leukemic blasts (3, 4). It serves as a receptor for C3bi (CR3) (5-7) 
and plays a role in neutrophil aggregation (8, 9) and neutrophiYmonocyte adhe- 
sion to substrates (lo- 12). LFA-1 (CD1 la/CD18 gp 177,95) is expressed by both 
lymphoid and myeloid cells and promotes lymphoid cell-adhesive interactions 
that include lymphocyte blastogenesis and cell-mediated cytotoxicity (13- 16). 
p150,95 (CDllc/CDl@, the third and most recently characterized member of the 
CD1 l/CD18 complex, is found on human neutrophils and monocytes (17, 18) and 
may contribute to the adherence of these cells to endothelial cell monolayers (19). 
An inherited deficiency in leukocyte expression of CDllKD18 glycoproteins is 
associated with impaired immunity against pyogenic microorganisms (see (20, 21) 
for review). 
The identification of the CDllCD18 glycoprotein complex has led to an inves- 
tigation of cellular mechanisms that modulate the expression of these adhesion- 
promoting glycoproteins on the plasma membrane of human leukocytes. It had 
previously been reported that the surface expression of several leukocyte re- 
ceptor structures such as the receptors for C3b (CRI) and fMLP were increased 
as a result of isolation procedures or after exposure of the cells to various factors 
that mimic the effects of inflammatory or chemotactic stimuli (22, 23). On the 
basis of these observations, we and others examined human peripheral blood 
neutrophils and monocytes to determine if the surface expression of the CDlli 
CD18 glycoproteins were affected in a similar fashion. It was found that exposure 
of neutrophils to soluble activating factors such as calcium ionophore A23187, 
N-L-formyl-L-leucyl-L-phenylalanine (fMLP), or phorbol myristate acetate 
(PMA) resulted in a 5- to lo-fold increase in surface Mol (24-26) and p150,95 (17, 
18) expression; the surface density of LFA-1 was relatively unaffected by this 
stimulation (17, 25). Whereas peripheral blood monocytes purified by adherence 
to plastic substrate failed to exhibit significant change in Mol or LFA-1 expres- 
sion in response to A23187, PMA, or fMLP (27), it was found that elutriation-pu- 
rified or unfractionated mononuclear cell monocytes did respond to soluble 
stimuli (C5a and fMLP) with an increase in Mol (28) and p150,95 (18). 
While these observations suggest that CDll/CD18 glycoprotein expression by 
circulating monocytes may be under regulatory control, little is known about the 
expression of the CDlKD18 complex by members of the human mononuclear 
phagocyte system that exist outside of the intravascular compartment, i.e., tissue 
macrophages. These cells contribute to the “front line” defense against patho- 
genic microorganisms and could rely on the CD1 l/CD18 surface glycoproteins to 
facilitate adhesion-dependent interactions. In order to determine if representative 
tissue macrophages respond to inflammatory factors with an up-modulation of 
surface Mol, LFA-1, and p150,95 expression, we have made a comparison of 
CD1 l/CD18 glycoprotein expression by peripheral blood monocytes, pulmonary 
alveolar macrophages (PAM), and breast milk macrophages (BMM) before and 
after stimulation of these cells by exposure to soluble factors (calcium ionophore 
A23187, PMA, and fMLP) that up-modulate CDlKD18 surface density by pe- 
ripheral blood neutrophils. By surface immunofluorescence analysis, we have 
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found that the expression of Mel, p150,95. and, to a lesser extent, LFA-1, is 
up-regulated by brief exposure of monocytes to soluble activating factors at 37”C, 
when compared to baseline antigen expression by monocytes subjected to min- 
imal isolation processing and maintained at 4°C. In contrast to the capacity of 
monocytes and neutrophils to respond to activating stimuli with an increase in 
CD1 l/CD18 expression, differentiated macrophages, as represented by PAM and 
BMM, do not exhibit significant alteration in surface antigen density. Baseline 
antigen expression by macrophages is heterogenous, ranging from negligible to 
barely detectable CD1 l/CD18 expression by PAM, and variable degrees of CD1 li 
CD18 expression by BMM. The potential physiological significance of these 
findings is discussed. 
MATERIALS AND METHODS 
Reagents. The following reagents were purchased from Sigma Chemical Co. 
(St. Louis, MO): calcium ionophore A23187 (C-7522), fMLP (F-3506), PMA 
(P-8139), and dimethylsulfoxide (DMSO, D-5879). A23187, fMLP, and PMA were 
dissolved in DMSO and stored as stock solutions at -80°C until used. Fluores- 
cein isothiocyanate-conjugated goat anti-mouse IgG + IgM antibodies were ob- 
tained from Tago, Inc. (Burlingame, CA). 
Solutions. Phosphate-buffered saline (PBS, without calcium or magnesium) and 
Dulbecco’s phosphate-buffered saline (DPBS) were mixed according to standard 
formulations using reagent grade chemicals. Hanks’ balanced salt solution 
(HBSS) was obtained from KC Biologicals (LM-218, Lenexa, KS). 
Monoclonal antibodies. The generation and characterization of murine mono- 
clonal antibodies anti-MO1 (anti-CDllb, IgG2a; clone 44) (5), anti-LFA-1 (anti- 
CD1 la, IgGl; clone Lll) (15), anti-p150,95 (anti-CD1 lc, IgGl; clone L29) (M. A. 
Arnaout and L. L. Lanier, unpublished results, July 1986), anti-p (anti-CD18, 
IgG2a; clone IB4) (7), anti-Ia (IgG2a; clone 9-49) (29), anti-Mb1 (IgGl; clone U42) 
(30), anti-J5 (anti-CDlO, IgG2a) (31), and anti-MO2 (anti-CD14, IgG2b) (32) have 
been described. Antibodies Lll, L29, and IB4 were gifts from Drs. Hergen Spits 
(Netherlands Cancer Institute, Amsterdam), Lewis L. Lanier (Becton-Dick- 
inson Monoclonal Center, Mountain View, CA), and Samuel D. Wright (Rocke- 
feller University, New York, NY), respectively. Antibody-containing ascites was 
used in all immunofluorescence assays (with the exception of antibody IB4 which 
was purified immunoglobulin). 
Isolation of human cells. After Human Protection Committee approval and in- 
formed consent, specimens of human cells were obtained either from normal vol- 
unteers or from patients undergoing diagnostic procedures. Peripheral blood leu- 
kocytes were obtained by venipuncture of volunteer adult donors. Heparinized 
whole blood specimens were diluted 1:l with HBSS, underlaid with Ficoll-Hy- 
paque (Histopaque-1077, Sigma Diagnostics), and subjected to density gradient 
centrifugation (33) for 25 min at 25°C. All subsequent steps were carried out at 
4°C. The granulocyte-erythrocyte pellet was washed once with PBS and sub- 
jected to distilled water lysis for 45 sec. Isotonicity was restored, and granulo- 
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cytes were washed in PBS and resuspended in DPBS. Viability was consistently 
>90% by trypan blue staining. Mononuclear cells from the Ficoll-Hypaque in- 
terface layer were washed twice in PBS and resuspended in DPBS. Viability was 
consistently >85%. 
Pulmonary alveolar macrophages (PAM) were recovered from the bronchoal- 
veolar lavage fluid either of normal volunteers or of patients undergoing diag- 
nostic bronchoscopy (for evaluation of isolated pulmonary nodules). Donors in- 
cluded both smokers and nonsmokers. Specimens were filtered through loose 
gauze to remove mucous strands, diluted in PBS, washed once, and resuspended 
in DPBS (all steps at 4°C). Specimens were 94% + 8 macrophages (as assessed in 
7116 specimens) by morphologic criteria (Wright-Geimsa staining). 
Breast milk macrophages (BMM) were isolated from breast milk (15-150 ml) 
donated by normal lactating volunteers who were generally less than 1 week 
postpartum (range 1 day to 9 months). Milk (or colostrum) was diluted 1: 1 with 
HBSS and cells were pelleted, washed twice with PBS, and resuspended in 
DPBS. Specimens were 78% + 1 I macrophages (as assessed in 6/l 1 specimens) 
by morphologic criteria and were kept at 4°C throughout. 
In vitro stimulation of leukocytes. Leukocytes were suspended in DPBS at a 
concentration of 2-10 x lo6 cells/ml and placed in polypropylene culture tubes 
(Falcon Plastics, Oxnard, CA). The cells were stimulated by the addition of 
A23187 (1 p&4), fMLP (0.1 FM), or PMA (0.1 &ml) and incubated for 15 min at 
37°C. Control cells received an equivalent amount of DMSO diluent (0.1% v/v) 
and were incubated for 15 min at either 4 or 37°C. Cells were then diluted in 
ice-cold PBS, pelleted, and resuspended in immunofluorescence wash buffer 
(DPBS containing 0.1% (w/v) glucose and 1 mg/ml Pentex human gamma glob- 
ulins (82-310-2, ICN Immunobiologicals, Lisle, IL)). 
ZmmunoJluorescence flow cytometric analysis. Aliquots (100 ~1) containing 
0.2-2.0 x lo6 cells were subjected to indirect immunofluorescence staining for 
the expression of CDllKD18 determinants, Mo2 (CD14), and Ia relative to 
background staining using isotype-identical negative controls (anti-Ia, J5, or 
Mbl). as described (34). All antibodies were used in excess to assure saturation 
of all antigenic sites. Intact, viable cells were selected by bit map gating (log 
forward vs log 90” light scatter). Positive staining for Mol , Mo2, and Ia plus Mo2 
was used to select for neutrophils, monocytes, and macrophages, respectively. 
Immunofluorescence intensity as a measure of relative antigen expression was 
analyzed on a Coulter Electronics (Hialeah, FL) EPICS C flow cytometer with 
the use of a logarithmic amplifier. The channel number (log scale) representing 
the mean fluorescence intensity (major fluorescence peak) of 5000 cells exposed 
to either experimental or isotype-identical negative control antibodies was deter- 
mined. The corresponding linear fluorescence intensity channel was calculated 
from a logarithmic-linear calibration formula (35). Specific fluorescence intensity 
represents the computed mean channel number (O-230 channels, linear scale) of 
cells stained with the experimental monoclonal antibody minus the mean channel 
of cells stained with the negative control reagent. For each experiment shown in 
Tables 1, 2, and 3, the mean fluorescence intensity (linear channel number) of 
cells stained with the negative control antibody is indicated in parentheses. 
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RESULTS 
When human monocytes within the mononuclear cell fraction obtained by Fi- 
toll-Hypaque density gradient centrifugation were exposed to A23 187 (I p1M) for 
1.5 min at 37°C and subsequently examined for the expression of the CD1 l/CD18 
epitopes of Mol , LFA-I , and p150,95, a reproducible increase in all three glyco- 
proteins was observed, as compared to mononuclear cells kept at 4°C prior to 
immunofluorescence analysis (Table 1). As previously observed for the neutrophil 
(17,24,25), the most consistent increases were seen in the surface density of Mol 
and pl50,95 (5.7- and 7.2-fold, respectively (median of 13 determinations), while 
the increase in LFA- 1 was less dramatic (2. l-fold). Exposure of the mononuclear 
cells to fMLP (0.1 ~.uV) or PMA (0.1 pg/ml) under the same conditions stimulated 
increases of lesser magnitude (2.0-, 1.6-, and 2.2-; 1.8-, I .5-, and 1.9-fold median 
increase (n = 4) for Mel, LFA-1, and pl50,95 after fMLP and PMA stimulation, 
respectively). Warming of the mononuclear fraction (37°C for 1.5 min in DPBS 
containing DMSO diluent alone) resulted in -fold median increases in monocyte 
Mel, LFA-I, and pl50,95 glycoprotein expression of 1.6, 1.3, and 1.5, respec- 
tively (n = 4). It is therefore evident that the monocyte, like the neutrophil, can 
respond to a stimulus (the contribution of warming in the presence of an inflam- 
matory agent) with an increase in the surface expression of the CD1 l/CD18 gly- 
coprotein complex. 
Since bone marrow-derived circulating monocytes may give rise to tissue mac- 
rophages during a process of differentiation (36), we next sought to determine 
whether the modulated expression of the CD1 I/CD18 glycoprotein complex is a 
consistent feature of the mononuclear phagocyte lineage. As representative ex- 
amples of tissue macrophages, we chose to examine pulmonary alveolar macro- 
phages (PAM) and breast milk macrophages (BMM) since these cells exist in fluid 
phase and require no purification processing prior to analysis. As shown in Table 
2, PAM demonstrated very little baseline expression of Mol or pl50,95 (as com- 
pared to background staining by isotypic negative control monoclonal reagents). 
Barely detectable expression of LFA-I (as indicated by anti-CDlla and anti- 
CD18 immunofluorescent staining) was observed in several specimens. Ia antigen 
expression was a consistent finding confirming the immunological identification 
of PAM. Exposure of PAM to A23187 under conditions that stimulated maximal 
increases in monocyte or neutrophil CDll/CD18 glycoprotein expression failed to 
up-modulate the surface density of these determinants by PAM (Table 2). In ex- 
periments not shown, there was little detectable expression of CD1 lb or CD18 
found in whole cell lysates of PAM subjected to SDS gel electrophoresis and 
Western blotting. Thus, in the case of PAM, the CDlliCDl8 glycoprotein com- 
plex is minimally expressed and the magnitude of baseline expression is unaf- 
fected by exposure to A23187. In contrast, BMM (as shown in Table 3) generally 
expressed the constituents of the CD1 I/CD18 complex, but with considerable 
individual variation in baseline density, ranging from strongly positive (Experi- 
ment I, Table 3) to barely detectable levels of expression (Experiment 3, Table 3). 
Despite this individual variability in baseline CD1 l/CD18 expression, the failure 
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tigen density was a consistent observation seen in an analysis of 11 specimens. 
Therefore, BMM, like PAM, do not respond to the A23187 stimulus with an up- 
modulation in surface CDll/CD18 glycoprotein expression. This lack of respon- 
siveness serves to distinguish these macrophages from the circulating monocytes. 
DISCUSSION 
In this immunofluorescence analysis, we have examined CDllCD18 epitope 
expression by human mononuclear phagocytes from both intra- and extravascular 
compartments to determine if these cells, like the neutrophil, can up-modulate 
the surface density of Mol (CDllb/CD18), p150,95 (CDllc/CD18), and LFA-I 
(CDllaKD18). We have found that peripheral blood monocytes do express all 
four CD1 l/CD18 epitopes, and after brief exposure to calcium ionophore A23187 
at 37°C the surface expressions of monocyte Mol, p150,95, and LFA-1 increase 
by factors of 5.7, 7.2, and 2.1, respectively (as compared to surface antigen ex- 
pression of unstimulated monocytes kept at 4°C). Exposure of monocytes to 
PMA or to fMLP under the same conditions results in increases in epitope den- 
sity of lesser magnitude. Our observations are thus in general agreement with 
those of Yancey et al. (28) who demonstrated a 1.5-fold increase in Mol (CD1 lb/ 
CD18) expression by monocytes after exposure of these cells to C5a, and those of 
Springer et al. (18) who reported a 4- to 6-fold increase in monocyte p150,95 
(CD1 lcKD18) after stimulation by fMLP 
Since monocytes are immature members of the mononuclear phagocyte system 
that also includes extravascular tissue macrophages (36), we examined pulmo- 
nary alveolar and breast milk macrophages (PAM and BMM, respectively) to de- 
termine if these cells, as examples of differentiated mononuclear phagocytes, ex- 
press CD1 l/CD18 glycoproteins, and, if so, whether surface glycoprotein expres- 
sion is under regulatory control. On the basis of an analysis of nine specimens of 
PAM (isolated from normal or patient volunteers, both smokers and non- 
smokers), there was negligible CD1 lb and CD1 lc epitope expression above back- 
ground staining; CD1 la and CD18 epitope expression was generally detectable at 
low antigen density. PAM therefore exhibit little, if any, surface Mol and p150,95, 
but do express some LFA-I glycoprotein. Exposure of these cells to A23187 (the 
stimulus inducing the greatest increase in the neutrophil and monocyte glycopro- 
tein expression) failed to stimulate a detectable rise in CDIlKD18 antigen den- 
sity. To exclude the possibility that our failure to detect significant surface Mol 
and p150,95 expression was due to either a “masking” or degradation of surface 
antigenic sites by blocking factors or proteases in the lavage fluid (37), we sub- 
jected whole cell lysates of PAM to SDS-polyacrylamide gel electrophoresis and 
Western blotting using polyclonal antisera specific for CD1 lb and CD18. As com- 
pared to parallel Western blots of neutrophil lysates, there was neglible expres- 
sion of CD1 1 b and barely detectable expression of CD18. These results are con- 
sistent with the notion that there is little cytoplasmic or surface expression of 
Mol and p150,95 (and relatively little expression of LFA-1) and that expression is 
not up-modulated by exposure to A23187. In contrast, macrophages isolated from 
human breast milk do express detectable levels of surface Mol, p150,95, and 
LFA-I glycoproteins although the baseline (unstimulated) level of expression 
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varied considerably among specimens (n = 11, ranging from barely detectable 
expression to high antigen density). The source of this individual variability is not 
clear since all specimens were maintained at 4°C prior to a single wash step and 
subsequent immunofluorescence analysis, and antigen density did not correlate 
with other variables such as the number of days postpartum (generally l-7 days; 
range 1 day to 9 months) that the sample was collected. What was consistent 
among all specimens was a failure to exhibit up-modulation of the CD1 l/CD18 
epitopes after exposure to activating stimuli.’ Therefore, on the basis of this im- 
munofluorescence analysis of CDll/CD18 glycoprotein expression by mononu- 
clear phagocytes, we conclude that monocytes, like neutrophils, can respond to 
activating stimuli with an increase in surface CDlKD18 glycoprotein expres- 
sion, but that CD1 l/CD18 expression by differentiated phagocytes may vary (de- 
pending upon anatomical location) and that control of surface expression is lost. 
These differences in CDlIKD18 expression may represent yet another example 
of the broad heterogeneity exhibited by members of the mononuclear phagocyte 
system (reviewed in Ref. (38)). 
The physiological significance of the capacity to modulate surface CD1 l/CD18 
expression as shown by neutrophils and monocytes but not by pulmonary al- 
veolar macrophages and breast milk macrophages is unclear. In the neutrophil, 
we and others have shown that exposure of cells to inflammatory stimuli that 
increase surface expression of Mol and p150,95 also results in enhanced CR3 
activity (8) and promotes adhesion-dependent phenomena such as aggregation (8, 
9) and adherence to endothelial cell monolayers (11, 12). Since these activities are 
CD1 l/CD18 dependent (abrogated by certain anti-CD1 l/CD18-specific reagents), 
one could reasonably conclude that the heightened functional response is related 
to up-modulation in surface Mol and p150,95 expression (24). However, we have 
not excluded the possibility that an increase in functional capacity resulting from 
exposure of the cells to an inflammatory stimulus is instead due to a qualitative 
change in receptor structure (rather than simply to an increase in receptor 
number). Precedent for this possibility was reported by Wright et al. (39,40) who 
observed the “activation” of phagocytosis-promoting function of monocyte or 
neutrophil CR3 (Mel) by libronectin or PMA out of proportion to changes in 
receptor number. The reported “clustering” of CR3 receptors on the plasma 
membrane (41) or glycoprotein phosphorylation (40, 42) represents at least two 
qualitative changes that could result in enhanced functional competence. Thus, 
the physiological significance of CD1 l/CD18 up-modulation stimulated by acti- 
vating factors has not been unequivocally demonstrated. The fact that increases 
in neutrophil Mol density can occur in vivo (in the setting of inflammatory condi- 
tions such as hemodialysis leukopenia (8) and systemic lupus erythematosis (43)) 
does, however, suggest that the phenomenon is biologically relevant. In response 
to an inflammatory stimulus, monocytes and neutrophils may depend upon the 
enhanced expression of CD1 l/CD18 glycoproteins to facilitate contact with vas- 
’ The possibility that up-modulation of BMM CD1 l/CD18 glycoprotein occurs but is undetectable 
because of epitope modification is unlikely (monoclonal reagents detecting four distinct epitodes were 
employed) but represents an alternative explanation of these results. 
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cular endothelium, thus allowing emigration and diapedesis to inflammatory foci 
within affected tissue compartments. One could speculate that tissue macro- 
phages, having already breached the endothelial barrier during ontogeny, have no 
need to express and/or regulate the surface density of the CDllKD18 class of 
adhesion-promoting molecules. 
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